Itepekimab
- Generic Name
- Itepekimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2226742-52-3
- Unique Ingredient Identifier
- WV9KZ9PS1A
- Background
Itepekimab is under investigation in clinical trial NCT03546907 (Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-il-33 Mab) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)).
- Associated Conditions
- -
- Associated Therapies
- -
Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD
Phase 2
Active, not recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 50
- Registration Number
- NCT05326412
- Locations
- 🇺🇸
UCLA Medical Center - Harbor- Site Number : 8400006, Torrance, California, United States
🇺🇸National Jewish Health Medical Center- Site Number : 8400012, Denver, Colorado, United States
🇺🇸University of Miami UHealth Tower- Site Number : 8400015, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath